Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Items 301–400 of 1,003
Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry
Li, C., Pazgier, M., Li, J., Li, C., Liu, M., Zou, G., Li, Z., Chen, J., Tarasov, S. G., Lu, W.-Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116814 · Cited by 79
Rudolph, J. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2087 · Cited by 90
“As for most other knowledge about protein–protein interactions, the best inhibitors discovered so far have been for stable, not transient, protein complexe”
How to design a drug for the disordered proteins?
Chen, C. Y., & Tou, W. I. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.04.008 · Cited by 80
Identification of small-molecule binding pockets in the soluble monomeric form of the Aβ42 peptide
Zhu, M., De Simone, A., Schenk, D., Toth, G., Dobson, C. M., & Vendruscolo, M. (2013) · The Journal of Chemical Physics · doi:10.1063/1.4811831 · Cited by 83
The T-box transcription factor T-bet in immunity and autoimmunity.
Peng, S. L. (2006) · PubMed · Cited by 87
Single-molecule fingerprinting of protein-drug interaction using a funneled biological nanopore
Jeong, K., Ryu, M., Kim, J., Kim, M., Yoo, J., Chung, M., Oh, S., Jo, G., Lee, S., Kim, H. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37098-4 · Cited by 86
Sadowsky, J., Murray, J. K., Tomita, Y. A., & Gellman, S. H. (2007) · ChemBioChem · doi:10.1002/cbic.200600546 · Cited by 79
Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
Semba, C. P., & Gadek, T. R. (2016) · Clinical ophthalmology · doi:10.2147/opth.s110557 · Cited by 77
Hu, X., Sun, J., Wang, H.-G., & Manetsch, R. (2008) · Journal of the American Chemical Society · doi:10.1021/ja802683u · Cited by 75
Wang, J., Wei, Y., Hu, X., Fang, Y., Li, X., Liu, J., Wang, S., & Yuan, Q. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b04894 · Cited by 79
Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein
Wang, L., Wu, Y. L., Yao, S., Ge, H., Zhu, Y., Chen, K., Chen, W., Zhang, Y., Zhu, W. J., Wang, H., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00735-z · Cited by 79
Rainard, J. M., Pandarakalam, G. C., & McElroy, S. P. (2018) · SLAS DISCOVERY · doi:10.1177/2472555217744728 · Cited by 75
Lee, T., Christov, P. P., Shaw, S., Tarr, J. C., Zhao, B., Veerasamy, N., Jeon, K. O., Mills, J. J., Bian, Z., Sensintaffar, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01991 · Cited by 77
Heterocyclic α-helix mimetics for targeting protein–protein interactions
Biros, S. M., Moisan, L., Mann, E., Carella, A., Zhai, D., Reed, J. C., & REBEK, J. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.075 · Cited by 75
Fragment-based drug discovery and its application to challenging drug targets
Price, A. J., Howard, S., & Cons, B. D. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170029 · Cited by 87
Systems Biology Brings New Dimensions for Structure-Based Drug Design
Pei, J., Yin, N., Ma, X., & Lai, L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504810z · Cited by 73
Buck, E. A., & Wells, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500016102 · Cited by 80
Self-citationNg, P. Y., Tang, Y., Knosp, W. M., Stadler, H. S., & Shaw, J. T. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700762 · Cited by 77
Fu, Z., Wang, L., Cui, H., Peng, J., Wang, S., Geng, J., Liu, J.-D., Feng, F., Song, F., Li, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6990 · Cited by 73
The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function
Wan, L., Chen, M., Cao, J., Dai, X., Yin, Q., Zhang, J., Song, S.-J., Lu, Y., Liu, J., Inuzuka, H., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0647 · Cited by 74
“S4R), indicating a possible mechanism that FZR1 interferes with BRAF dimerization through an interaction-induced conformational change, i.e. FZR1 might function as an allosteric inhibitor for the BRAF dimerization (52).”
Sijbesma, E., Visser, E., Plitzko, K., Thiel, P., Milroy, L.-G., Kaiser, M., Brunsveld, L., & Ottmann, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17741-0 · Cited by 72
Fixierung cyclischer Peptide: Mimetika von Proteinstrukturmotiven
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie · doi:10.1002/ange.201401058 · Cited by 74
Current strategies and progress for targeting the “undruggable” transcription factors
Zhuang, J., Liu, Q., Wu, D., & Tie, L. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00852-9 · Cited by 79
“Mutational analysis of protein surfaces reveal that usually a limited number of key residues contribute to most of the binding energy, suggesting that inhibition of PPIs by small molecules is feasible [54].”
BackgroundResearch in the Field of Drug Design and Development
Biała, G., Kędzierska, E., Kruk-Słomka, M., Orzelska‐Górka, J., Hmaidan, S., Skrok, A., Kamiński, J. W., Havránková, E., Nádaská, D., & Malík, I. (2023) · Pharmaceuticals · doi:10.3390/ph16091283 · Cited by 72
“The value could not be viewed so strictly, several scientific papers regarded the interval 900–1000 Da as the upper (fixed) limit [55,56], in fact.”
BackgroundLoregian, A., & Coen, D. M. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.12.002 · Cited by 72
Drug discovery and the human kinome: Recent trends
Eglen, R. M., & Reisine, T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.007 · Cited by 85
Targeting protein−protein interfaces using macrocyclic peptides
Gao, M., Cheng, K., & Yin, H. H. (2015) · Biopolymers · doi:10.1002/bip.22625 · Cited by 78
Al‐Mawsawi, L. Q., & Neamati, N. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.09.005 · Cited by 82
Park, J. G., Sill, P. C., Makiyi, E. F., García‐Sosa, A. T., Millard, C. B., Schmidt, J. J., & Pang, Y. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.08.018 · Cited by 72
Gan, Z., Reddy, P. T., Quevillon, S., Couve‐Bonnaire, S., & Arya, P. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462298 · Cited by 72
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Modulating Protein–Protein Interactions with Small Molecules: The Importance of Binding Hotspots
Thangudu, R. R., Bryant, S. H., Panchenko, A. R., & Madej, T. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.026 · Cited by 71
Virus maturation as a new HIV-1 therapeutic target
Adamson, C. S., Salzwedel, K., & Freed, E. O. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903039714 · Cited by 70
“Identification and development of inhibitors that target protein–protein interfaces is challenging as the interacting surfaces may be flat and cover relatively large areas [111].”
BackgroundBaleja, J., Cherry, J. J., Liu, Z., Gao, H., Nicklaus, M. C., Voigt, J. H., Chen, J. J., & Androphy, E. J. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.03.014 · Cited by 82
“Low molecular weight compounds that target the papillomavirus E6 protein represent a significant advance in finding inhibitors of protein-protein interactions (Arkin and Wells, 2004).”
BackgroundChemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy
Mori, T., Kikuchi, E., Watanabe, Y., Fujii, S., Ishigami‐Yuasa, M., Kagechika, H., Sohara, E., Rai, T., Sasaki, S., & Uchida, S. (2013) · Biochemical Journal · doi:10.1042/bj20130597 · Cited by 71
β-Peptides with improved affinity for hDM2 and hDMX
Harker, E. A., Daniels, D. S., Guarracino, D. A., & Schepartz, A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.01.039 · Cited by 71
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS
Ramharter, J., Kessler, D., Ettmayer, P., Hofmann, M. H., Gerstberger, T., Gmachl, M., Wunberg, T., Kofink, C., Sanderson, M., Arnhof, H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01949 · Cited by 62
Binding Site Identification and Structure Determination of Protein–Ligand Complexes by NMR
Ziarek, J. J., Peterson, F. C., Lytle, B. L., & Volkman, B. F. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-381274-2.00010-8 · Cited by 75
“The success of this study and others (Arkin and Wells, 2004; Berg, 2008; Fuller et al., 2009) demonstrates the value of NMR binding data to identify epitopes for virtual screening within the rational drug development process.”
BackgroundSmall-Molecule Inhibitors of IL-2/IL-2R: Lessons Learned and Applied
Wilson, C. G. M., & Arkin, M. R. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_93 · Cited by 86
“The discovery of interaction hotspots indicated that smaller – and therefore more druggable – sites might exist within PPI interfaces (Arkin and Wells 2004; Wells and McClendon 2007).”
BackgroundMethodInfluentialSelf-citationα-Helix mimetics as inhibitors of protein–protein interactions
Saraogi, I., & Hamilton, A. D. (2008) · Biochemical Society Transactions · doi:10.1042/bst0361414 · Cited by 70
Moreira, I. S., Fernandes, P. A., & Ramos, M. J. (2006) · The Journal of Physical Chemistry B · doi:10.1021/jp054760d · Cited by 70
Tedford, H. W., Gilles, N., Ménèz, A., Doering, C. J., Zamponi, G. W., & King, G. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404006200 · Cited by 69
Ahmed, M. H., Spyrakis, F., Cozzini, P., Tripathi, P. K., Mozzarelli, A., Scarsdale, J. N., Safo, M. A., & Kellogg, G. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024712 · Cited by 70
“Protein-protein complexes are under intense scrutiny as possible targets for new therapies, particularly in cancer [2,62,63] and amyloidogenic diseases [64,65].”
BackgroundCox, K. J., Shomin, C. D., & Ghosh, I. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.10.272 · Cited by 65
Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making
Roy, A., McDonald, P. R., Sittampalam, S., & Chaguturu, R. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110792927757 · Cited by 72
“The major challenge in obtaining orally available, small molecule drug-like compounds lies in defining surfaces and residues involved in intracellular protein-protein interactions [21, 22].”
BackgroundSmall-Molecule-Triggered and Light-Controlled Reversible Regulation of Enzymatic Activity
Tian, T., Song, Y., Wang, J., Fu, B., He, Z., Xu, X., Li, A., Zhou, X. H., Wang, S., & Zhou, X. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b11532 · Cited by 69
Toll-like receptor signalling and the clinical benefits that lie within
Verstak, B., Hertzog, P. J., & Mansell, A. S. (2007) · Inflammation Research · doi:10.1007/s00011-007-6093-7 · Cited by 79
Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents
Buolamwini, J., Addo, J., Kamath, S., Patil, S., Mason, M., & Ores, M. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332672 · Cited by 69
Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate
Anand, U., Bandyopadhyay, A., Jha, N. K., de la Lastra, J. M. P., & Dey, A. (2022) · BioFactors · doi:10.1002/biof.1913 · Cited by 76
“While the large surface area of the compound does not provide a significant advantage over competing small molecules, it can induce antagonistic interactions via allosteric receptors.(46) However, there are exceptions where antagonists have been developed for targets that required large surface area and complex struct…”
BackgroundTargeting protein–protein interactions in complexes organized by A kinase anchoring proteins
Calejo, A., & Taskén, K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00192 · Cited by 66
“Small molecules can also allosterically bind to one of the two interacting proteins outside the binding interface inducing conformational changes affecting the PPI (Arkin and Wells, 2004; Fry, 2006; Wells and McClendon, 2007; Turnbull et al., 2014).”
BackgroundSmall Molecule Modulators of Transcription
Arndt, H. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600285 · Cited by 68
Catalytic Stereoselective Synthesis of Diverse Oxindoles and Spirooxindoles from Isatins
MacDonald, J. P., Badillo, J. J., Arevalo, G. E., Silva‐Garcia, A., & Franz, A. K. (2012) · ACS Combinatorial Science · doi:10.1021/co300003c · Cited by 67
Current Challenges and Opportunities in Designing Protein–Protein Interaction Targeted Drugs
Shin, W.-H., Kumazawa, K., Imai, K., Hirokawa, T., & Kihara, D. (2020) · Advances and Applications in Bioinformatics and Chemistry · doi:10.2147/aabc.s235542 · Cited by 64
Chan, L. L., Pineda, M. F., Heeres, J. T., Hergenrother, P. J., & Cunningham, B. T. (2008) · ACS Chemical Biology · doi:10.1021/cb800057j · Cited by 70
Adding Diverse Noncanonical Backbones to Rosetta: Enabling Peptidomimetic Design
Drew, K., Renfrew, P. D., Craven, T. W., Butterfoss, G. L., Chou, F.-C., Lyskov, S., Bullock, B. N., Watkins, A., Labonte, J. W., Pacella, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067051 · Cited by 67
“enzymes and receptors) while protein-protein interactions have been considered difficult targets because of their larger and relatively flat interfaces [58].”
BackgroundStructure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors
Johannes, J. W., Bates, S. M., Beigie, C., Belmonte, M. A., Breen, J. N., Cao, S., Centrella, P. A., Clark, M., Cuozzo, J. W., Dumelin, C. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00464 · Cited by 67
Shaw, S., Bian, Z., Zhao, B., Tarr, J. C., Veerasamy, N., Jeon, K. O., Belmar, J., Arnold, A. L., Fogarty, S. A., Perry, E., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01155 · Cited by 69
Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions
Raj, M., Bullock, B. N., & Arora, P. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.023 · Cited by 66
Stabilizer‐Guided Inhibition of Protein–Protein Interactions
Milroy, L. ‐., Bartel, M., Henen, M. A., Leysen, S., Adriaans, J. M. C., Brunsveld, L., Landrieu, I., & Ottmann, C. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201507976 · Cited by 66
Bach, A., Celestine, N., Olsen, T. B., Pedersen, S. W., Røder, M. U., Pang, G. F., Clausen, R. P., Jemth, P., & Strømgaard, K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800836w · Cited by 71
Mao, C., Patterson, N. M., Cherian, M. T., Aninye, I. O., Zhang, C., Montoya, J. B., Cheng, J., Putt, K. S., Hergenrother, P. J., Wilson, E. M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709936200 · Cited by 66
Development of small molecules designed to modulate protein–protein interactions
Che, Y., Brooks, B. R., & Marshall, G. R. (2006) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-006-9040-8 · Cited by 72
Completion of a programmable DNA-binding small molecule library
Hsu, C. F., Phillips, J. W., Trauger, J. W., Farkas, M. E., Belitsky, J. M., Heckel, A., Olenyuk, B. Z., Puckett, J. W., Wang, C. C. C., & Dervan, P. B. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.03.041 · Cited by 66
Wendt, M. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.9.1123 · Cited by 67
“In retrospect, this was not a surprising result, and many reviews of PPIs touch on the frequent failure of highthroughput screening toward PPI targets [17,18] .”
BackgroundESI-IMS–MS: A method for rapid analysis of protein aggregation and its inhibition by small molecules
Young, L. M., Saunders, J. C., Mahood, R. A., Revill, C. H., Foster, R. J., Ashcroft, A. E., & Radford, S. E. (2016) · Methods · doi:10.1016/j.ymeth.2015.05.017 · Cited by 65
Umumararungu, T., Gahamanyi, N., Mukiza, J., Habarurema, G., Katandula, J., Rugamba, A., & Kagisha, V. (2024) · Amino Acids · doi:10.1007/s00726-024-03410-9 · Cited by 73
“(Arkin and Wells 2004; Freund et al. 2008) However, a number of proline derivatives are produced by living organisms and some of them have been used as probes for the design of ligands of some receptors.”
BackgroundAccess to a Structurally Complex Compound Collection via Ring Distortion of the Alkaloid Sinomenine
Garcia, A., Drown, B., & Hergenrother, P. J. (2016) · Organic Letters · doi:10.1021/acs.orglett.6b02333 · Cited by 66
Beyond the Ligand-Binding Pocket: Targeting Alternate Sites in Nuclear Receptors
Caboni, L., & Lloyd, D. G. (2012) · Medicinal Research Reviews · doi:10.1002/med.21275 · Cited by 67
Pons, C., Talavera, D., de la Cruz, X., Orozco, M., & Fernandez-Recio, J. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci100353e · Cited by 66
Chen, L., Fu, W., Zheng, L., Wang, Y., & Liang, G. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.015 · Cited by 67
Long-range cooperative binding effects in a T cell receptor variable domain
Jalali, B. M., Buonpane, R. A., Zhu, P., Herfst, C. A., Rahman, A., McCormick, J. K., Kranz, D. M., & Sundberg, E. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600220103 · Cited by 64
Oh, M., Lee, J. H., Wang, W., Lee, H. S., Lee, W. S., Burlak, C., Im, W., Hoang, Q. Q., & Lim, H.-S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320556111 · Cited by 64
Kanoh, N., Asami, A., Kawatani, M., Honda, K., Kumashiro, S., Takayama, H., Simizu, S., Amemiya, T., Kondoh, Y., Hatakeyama, S., et al. (2006) · Chemistry - An Asian Journal · doi:10.1002/asia.200600208 · Cited by 63
Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain
Zhang, H., Curreli, F., Zhang, X., Bhattacharya, S., Waheed, A. A., Cooper, A., Cowburn, D., Freed, E. O., & Debnath, A. K. (2011) · Retrovirology · doi:10.1186/1742-4690-8-28 · Cited by 63
“Therefore, it has been established that inhibitors do not have to block the entire binding surface but targeting the ‘hot spots’ may be sufficient to inhibit proteinprotein interactions [51,52].”
BackgroundToxin-Antitoxin Genes of the Gram-Positive Pathogen Streptococcus pneumoniae: So Few and Yet So Many
Chan, W. T., Moreno‐Córdoba, I., Yeo, C. C., & Espinosa, M. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00030-12 · Cited by 74
“The use of naturally occurring peptide antibiotics or peptide-based inhibitors as design templates for the synthesis of compounds with similar physiochemical properties is also an approach used in pharmaceutical research (7).”
BackgroundAFM-based force spectroscopy for bioimaging and biosensing
Li, Q., Zhang, T., Pan, Y., Ciacchi, L. C., Xu, B., & Wei, G. (2016) · RSC Advances · doi:10.1039/c5ra22841g · Cited by 67
Interaction entropy for computational alanine scanning in protein–protein binding
Qiu, L., Yan, Y., Sun, Z., Song, J., & Zhang, J. Z. H. (2017) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1342 · Cited by 71
Jung, S. O., Ro, H., Kho, B. H., Shin, Y., Kim, M., & Chung, B. H. (2005) · PROTEOMICS · doi:10.1002/pmic.200500001 · Cited by 70
Khamlichi, C. E., Reverchon, F., Hervouet, N., Blot, L., Reiter, É., & Morisset‐Lopez, S. (2019) · Molecules · doi:10.3390/molecules24030537 · Cited by 73
“They are frequently deemed as ‘undruggable targets’ due to their highly dynamic structures with shallow binding surface [4].”
BackgroundZhao, L., & Lu, W. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.09.019 · Cited by 63
What induces pocket openings on protein surface patches involved in protein–protein interactions?
Eyrisch, S., & Helms, V. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9239-y · Cited by 74
Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors
Lee, T., Bian, Z., Zhao, B., Hogdal, L. J., Sensintaffar, J., Goodwin, C. M., Belmar, J., Shaw, S., Tarr, J. C., Veerasamy, N., et al. (2016) · FEBS Letters · doi:10.1002/1873-3468.12497 · Cited by 70
“However, Mcl-1 mediates its effects through protein-protein interactions[14] and is considered difficult to target with small molecules.”
BackgroundKim, D., Ko, Y., Kwon, G., Choo, Y.-M., & You, J. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.07.107 · Cited by 62
Assigning functionality to cysteines by base editing of cancer dependency genes
Li, H., Ma, T., Remsberg, J. R., Won, S. J., DeMeester, K. E., Njomen, E., Ogasawara, D., Zhao, K. T., Huang, T. P., Lu, B., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01428-w · Cited by 62
Mammalian two-hybrids come of age
Lievens, S., Lemmens, I., & Tavernier, J. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.06.009 · Cited by 62
Kuenemann, M. A., Spérandio, O., Labbé, C. M., Lagorce, D., Miteva, M. A., & Villoutreix, B. O. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.02.006 · Cited by 64
Organoplatinum-Substituted Polyoxometalate Inhibits β-amyloid Aggregation for Alzheimer's Therapy.
Zhao, J., Li, K., Wan, K.-W., Sun, T.-D., Zheng, N., Zhu, F., Ma, J., Jiao, J., Li, T.-C., Ni, J., et al. (2019) · Angewandte Chemie · doi:10.1002/anie.201910521 · Cited by 48
Wu, B., Barile, E., De, S. K., Wei, J., Purves, A., & Pellecchia, M. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150519102459 · Cited by 65
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie · doi:10.1002/ange.201201358 · Cited by 61
Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly
Erlanson, D. A., & Hansen, S. K. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.010 · Cited by 76
Friedler, A., Veprintsev, D. B., Rutherford, T., von Glos, K. I., & Fersht, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411176200 · Cited by 61
Template-constrained macrocyclic peptides prepared from native, unprotected precursors
Lawson, K. V., Rose, T. E., & Harran, P. G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311706110 · Cited by 60
Massari, S., Goracci, L., Desantis, J., & Tabarrini, O. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01474 · Cited by 60
Xu, J., Miao, H., Zou, L., Bui, B. T. S., Haupt, K., & Pan, G. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202106657 · Cited by 60
How does a small molecule bind at a cryptic binding site?
Shan, Y., Mysore, V. P., Leffler, A. E., Kim, E. T., Sagawa, S., & Shaw, D. E. (2022) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009817 · Cited by 60
“Whereas conventional drugs often bind to well-defined pockets or clefts that are present even in the absence of a ligand, binding sites at PPI interfaces tend to be “cryptic”: In the absence of a ligand, cryptic binding sites predominantly adopt a relatively flat and featureless conformation, but when bound to a ligan…”
BackgroundStricher, F., Huang, C.-C., Descours, A., Duquesnoy, S., Combes, O., Decker, J. M., Kwon, Y. D., Lusso, P., Shaw, G. M., Vita, C., et al. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.06.069 · Cited by 66
β-Hairpin protein epitope mimetic technology in drug discovery
Obrecht, D., Chevalier, É., Moehle, K., & Robinson, J. A. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.07.006 · Cited by 59
The p53-mediated cytotoxicity of photodynamic therapy of cancer: Recent advances
Zawacka‐Pankau, J., Krachulec, J., Grulkowski, I., Bielawski, K. P., & Selivanova, G. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.07.012 · Cited by 70
Coleman, N., & Rodon, J. A. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_325885 · Cited by 62
Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics
Korzhnev, D. M., & Hadden, M. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00596 · Cited by 58
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.